Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Globus Medical, Inc. is a publicly traded medical device company focused on the development, manufacturing, and commercialization of musculoskeletal solutions, primarily for spine surgery. The company operates within the medical devices and orthopedic implants industries, serving hospitals, ambulatory surgery centers, and surgeons. Its core offerings include implant systems, surgical instruments, biologics, and enabling technologies designed to improve clinical outcomes and procedural efficiency.
Founded in 2003, Globus Medical differentiated itself through surgeon-driven innovation, rapid product development cycles, and a vertically integrated manufacturing model. A defining milestone in its evolution was the 2023 merger with NuVasive, Inc., which significantly expanded its scale, technology portfolio, and global reach. Following this transaction, Globus Medical positioned itself as one of the largest pure-play spine technology companies globally.
Business Operations
Globus Medical generates revenue primarily through the sale of spinal implants, orthopedic solutions, and associated surgical instrumentation. Its reportable operating segments include Musculoskeletal Solutions and Enabling Technologies, which together encompass spine fixation systems, interbody fusion devices, motion preservation technologies, trauma implants, and robotic-assisted surgery platforms. Revenue is largely procedure-driven, tied to surgical volumes and hospital capital equipment purchasing cycles.
The company operates through a combination of direct sales representatives and independent distributors, with a strong emphasis on direct sales in its largest markets. It controls proprietary technologies across implant design, navigation, and robotics, including its Excelsius platform. Subsidiaries resulting from the NuVasive merger and prior acquisitions support biologics, software, and surgical planning capabilities. Data on specific joint ventures beyond standard distribution arrangements is inconclusive based on available public sources.
Strategic Position & Investments
Globus Medical’s strategy centers on integrated procedural solutions that combine implants, imaging, navigation, and robotics to create differentiated surgical ecosystems. Growth initiatives emphasize international expansion, cross-selling opportunities from the NuVasive integration, and continued investment in enabling technologies that enhance surgical precision and efficiency.
The merger with NuVasive, Inc. represents the company’s most significant strategic investment, adding minimally invasive surgery technologies, advanced neuromonitoring, and a broader international sales infrastructure. The company continues to invest in robotic-assisted surgery, digital surgery platforms, and next-generation spinal and orthopedic implants. Public disclosures confirm ongoing R&D investment, though specific early-stage technology bets beyond disclosed platforms are not fully detailed in public filings.
Geographic Footprint
Globus Medical is headquartered in North America, with its principal executive offices in Pennsylvania, United States. The company maintains a significant presence across North America, Europe, Asia-Pacific, and Latin America, supported by manufacturing facilities, distribution centers, and sales offices.
International markets represent a growing portion of revenue following the NuVasive merger, which expanded Globus Medical’s footprint in Europe and Asia-Pacific. The company’s products are sold in dozens of countries, with varying degrees of direct operations versus distributor-based models. Manufacturing remains primarily U.S.-based, supporting its vertically integrated strategy.
Leadership & Governance
Globus Medical was founded by David C. Paul, whose vision emphasized surgeon collaboration and internal engineering capabilities. The company’s leadership philosophy continues to focus on innovation, operational control, and long-term product development rather than reliance on external manufacturing or licensing.
Key executives include:
- David C. Paul – Chief Executive Officer
- Keith R. Pfeil – Chief Financial Officer
- Timothy A. Adams – Chief Operations Officer
- Scott A. Bogie – Chief Technology Officer
- Thomas J. Tully – Chief Integration Officer
The board and executive team oversee governance with an emphasis on regulatory compliance, integration execution following the NuVasive transaction, and sustained investment in research and development.